PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
Condition: Colon Cancer Interventions: Drug: Panitumumab; Drug: Nivolumab; Drug: Ipilimumab Sponsors: UNC Lineberger Comprehensive Cancer Center; Amgen; Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials